Insulin at $35: Who Actually Benefits From the Medicare Drug Price Cap — and Who Gets Left Behind
The $35 monthly cap on insulin costs for Medicare enrollees was celebrated as a landmark victory for American patients. But the real-world impact of this policy depends heavily on which plan you carry, which insulin you use, and whether you fall inside or outside the Medicare umbrella entirely. This article breaks down exactly who benefits, how the savings are structured, and where significant gaps remain.
